Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus platinum and fluoropyrimidine versus placebo plus chemotherapy for first-line advanced gastric or gastroesophageal junction adenocarcinoma
2018-000312-24Phase 3Completed
- Sponsor
- BeiGene
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Tislelizumab plus platinum and fluoropyrimidine with Placebo plus platinum and fluoropyrimidine (2 arms). Primary endpoint: Overall survival. Started Dec 2018; status: completed.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2018-000312-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000312-24.